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1 |  INTRODUCTION
The reason for the clinical success of Bioglass 45S5,1 which 
has been used clinically since the mid‐1980s,2 is its ability to 
degrade in aqueous solution, release calcium and phosphate 
ions, form a surface layer of hydroxycarbonate apatite and 
thus allow for the formation of an intimate bond to bone.1 It 
has been described as a Class A bioactive material, bonding 
to both soft and hard tissue and degrading while being re-
placed by newly formed bone.3 Owing to its inherent release 
of ions, such as silicon ions, it stimulates cell cycling and 
obviates the need for supplementation with growth factors.4,5
Clinical applications of bioactive glasses are mainly in bone 
regeneration and dental remineralization,6 where they are used 
as either granules (ie, coarse particles) or fine powder. But one of 
the main advantages of glassy materials is their high‐temperature 
processing, which allows for shaping the material at elevated 
temperatures, to sinter coatings7,8 or complex structures.9,10 For 
bioactive glasses, however, this high‐temperature processing has 
not yet resulted in clinical or commercial products.
One reason is that Bioglass 45S5, which has a highly dis-
rupted silicate structure consisting of Q2 chains mostly with 
only small amounts (10%‐15%) of Q3 branching units,11,12 
shows a pronounced tendency to undergo devitrification 
upon heat treatment. This makes it challenging to process the 
glass without crystallization occurring.13 For bioactive glass 
applications, particularly in bone regeneration, the capac-
ity to sinter complex, three‐dimensional porous structures, 
so‐called scaffolds, would be of great interest as this could 
broaden the field of clinical applications. Potential uses in-
clude porous implant materials, which simulate the structure 
of trabecular bone or templates in tissue engineering13. In 
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Abstract
The sintering of bioactive glasses allows for the preparation of complex structures, 
such as three‐dimensional porous scaffolds. Such 3D constructs are particularly in-
teresting for clinical applications of bioactive glasses in bone regeneration, as the 
scaffolds can act as a guide for in‐growing bone cells, allowing for good integration 
with existing and newly formed tissue while the scaffold slowly degrades. Owing 
to the pronounced tendency of many bioactive glasses to crystallize upon heat treat-
ment, 3D scaffolds have not been much exploited commercially. Here, we investi-
gate the influence of crystallization on the sintering behavior of several bioactive 
glasses. In a series of mixed‐alkali glasses an increased CaO/alkali metal oxide ratio 
improved sintering compared to Bioglass 45S5, where dense sintering was inhibited. 
Addition of small amounts of calcium fluoride helped to keep melting and sintering 
temperatures low. Unlike glass 13‐93, these new glasses crystallized during sintering 
but this did not prevent densification. Variation in bioactive glass particle size al-
lowed for fine‐tuning the microporosity resulting from the sintering process.
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these applications, the porous scaffold acts as a 3D template, 
which ideally integrates well with existing tissue, allows for 
the ingrowth of cells, guides them to grow deep into the pores 
and stimulates them to form new bone but also allows for the 
growth of new blood vessels into this structure.
For this reason, this paper investigates the sintering be-
havior of Bioglass 45S5 and other bioactive glasses, to an-
alyze how crystallization affects sintering and the resulting 
microstructure of the materials.
2 |  EXPERIMENTAL PROCEDURE
2.1 | Glass and powder preparation
About 150 g batches of glass were prepared by a high‐tem-
perature melt‐quench route as described previously.14 Briefly, 
mixtures of SiO2, phosphates, carbonates, and CaF2 were sin-
tered together for 1 hour using a platinum crucible in an elec-
tric furnace at 1250°C, then melted for 1 hour at 1350°C. The 
melt was rapidly quenched into water, and the resulting glass 
frits were dried at 120°C. Glass monoliths were obtained by 
pouring the melt into brass moulds and annealing at the glass 
transition temperature before cooling to room temperature in 
the switched off furnace over night. Nominal glass composi-
tions are shown in Table 1.
Glass powders were obtained from glass frits by crush-
ing with a steel mortar and sieving into 32‐42 µm, 56‐63 µm, 
125‐140 µm, 180‐200 µm, 300‐315 µm, and 315‐3150 µm 
fractions. From the 315‐3150 µm fraction, powders were 
obtained by milling for 10 minutes in a planetary ball‐mill 
(Pulverisette 5/2; Fritsch, Idar‐Oberstein, Germany) using 
zirconia jars and milling balls. Milling was performed in 
isopropanol, and milled powders were dried in air at 55°C 
for half an hour. Glass powder particle size distribution 
was analyzed by light scattering (Mastersizer; Malvern, 
Worcestershire, UK) using a suspension of 10  mg glass 
powder dispersed in a 0.003  mol/L Na4P2O7 solution. 
Table 2 shows the particle size distribution of the milled 
glass powder, referred to as "<32 µm" hereafter.
Glass powder compacts were obtained by uniaxially press-
ing 0.1 g glass powder (<32 µm) twice for 30 seconds each 
at 50 MPa using cylinders of 5 mm in diameter and height. 
The relative density, ρrel, for all glass powder compacts was 
approximately 55%. Glass powders and powder compacts 
were stored in desiccators using P2O5 or silica gel in an argon 
atmosphere in a low vacuum.
2.2 | Density and thermal properties
Glass density measurements were performed on glass mono-
liths using He gas displacement pycnometry (AccuPyc 1330; 
Micromeritics, Norcross, GA; ±0.01  g  cm−3 accuracy). 
Results are presented in Table 1. Glass transition and crys-
tallization temperatures were determined using differential 
thermal analysis, DTA (TAG24; Setaram, Caluire, France; 
± 5 K accuracy) using 25 mg glass powder samples heated at 
10 K min−1 to 1300°C.
2.3 | Sintering
Sintering was studied on cylindrical powder compacts 
using a heating microscope (Leitz, Wetzlar, Germany). 
The compacts were placed on zirconia substrates 
(1.5 × 1 × 0.05 mm3; Ceramtec, Plochingen, Germany) and 
heated incrementally (30 K min−1 to 300°C then 20 K min−1 
to 450°C and 10  K  min−1 above 450°C). Owing to slight 
variations in sample positioning and furnace temperature 
distribution, temperature accuracy was about ±10 K. An in-
tegrated optical data acquisition system (Hesse Instruments, 
Osterode, Germany) recorded sample silhouette height (sH) 
and area (sA). Sintering shrinkage is presented as changes 
in sA or alternatively as changes in relative density (ρrel) 
calculated from sA, sH and glass density, ρ (Table 1) and 
the sample mass, m, assuming ideal cylinder geometry and 
isotropic shrinkage according to:
Heating microscopy was also used to obtain sintered spec-
imens for further analyses. Powder compacts were heated as 
described above but removed from the heating microscope at 
selected temperatures and quenched in air.
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Glass SiO2 CaO Na2O K2O MgO P2O3 CaF2 NC ρ
13‐93 54.6 22.1 6.0 7.9 7.7 1.7 — 2.6 2.65
45S5 46.1 26.9 24.4 — — 2.6 — 2.1 2.72
ICIE16 49.4 36.3 6.6 6.6 — 1.1 — 2.1 2.72
F0 46.1 37.6 6.8 6.8 — 2.6 — 2.1 2.75
F1 45.7 37.1 6.8 6.8 — 2.6 1.0 2.1 2.76
F3 44.8 36.5 6.6 6.6 — 2.5 3.0 2.1 2.76
F8 42.4 34.6 6.3 6.3 — 2.4 8.0 2.1 2.77
T A B L E  1  Nominal glass composition 
(mol%), network connectivity, NC12 and 
glass density, ρ (g cm−3; ± 0.01 g cm−3)
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2.4 | Scanning electron microscopy
Fractured sintered powder compacts were analyzed using 
scanning electron microscopy, (SEM; XL30 ESEM‐FEG, 
Philips, Eindhoven, the Netherlands) combined with energy 
dispersive X‐ray (EDX, EDAX Inc.) analysis was used for 
these studies. EDX spectra were obtained using a 15 kV ac-
celeration voltage at 0.3‐0.5 torr H2 pressure.
2.5 | X‐ray micro computed tomography
Micro computed tomography (µCT) on all samples with the 
exception of F3 (particle size 180‐200  µm) were performed 
at the I13‐2 beamline of the Diamond Manchester Imaging 
Branchline at the Diamond Light Source synchrotron, Harwell, 
Didcot, UK.15,16 Sintered powder compacts of approximately 
1‐2 mm in width were probed with polychromatic X‐rays in the 
energy range of 8‐30 keV and filtered with pyrolytic graphite 
(1.3 mm) and aluminium (3.2 mm) filters. The samples were 
rotated from 0 to 180° with an angular step size of 0.05°, col-
lecting a total of 3601 projections (transmitted X‐rays) with 
a 50 ms exposure. Transmitted X‐rays were imaged using a 
500 µm thick CdWO4 scintillator‐coupled sCMOS (2560x2160 
pixels) detector (PCOpco.edge 5.5; PCO AG, Germany), posi-
tioned 10 mm from the sample. Scans were performed with a 
total magnification of 20×, resulting in an effective isotropic 
pixel size of 0.33 µm. Projections were reconstructed into to-
mograms using a filtered back projection algorithm.17‒19
Sample F3 (180‐200 µm) was scanned on a laboratory X‐
ray sourced CT (Skyscan 1172; Bruker, Belgium) using 80 kV 
voltage and 124 µA current. Samples were rotated from 0° to 
360° with an angular step size of 0.1° collecting a total of 3601 
projections with a 900 ms exposure. Scans were performed with 
an overall isotropic voxel size of 1.5 µm. Projections were re-
constructed into tomograms using NRecon software (Bruker).
Tomograms were processed on Fiji.20 First a 3D median filter 
was applied to remove noise. Glass and pores were segmented by 
applying a threshold using the histogram. Pore fraction was cal-
culated from the threshold images. 3D rendering of the glasses 
were produced using the Volume Viewer plugin on Fiji.
2.6 | Infrared spectroscopy and X‐ray 
diffraction experiments
Sintered powder compacts were crushed with a steel mortar 
and milled twice for 30 seconds in an agate ball mill (KM1; 
Janetzki) for analysis by powder X‐ray diffraction (XRD; D8 
Advance; Bruker AXS, Karlsruhe, Germany; Cu‐Kα radia-
tion, scanning in 0.02° steps for 2  seconds in a 5 to 80°2θ 
range) and attenuated total reflection (ATR) Fourier‐trans-
form infrared spectroscopy (FTIR; Nicolet Avatar 370DTGS 
with art Orbit addition; Thermo Electron Corporation; 
525‐1700 cm−1).
3 |  RESULTS & DISCUSSION
Figure 1A,B illustrate changes in the silhouette area of 
powder compacts during heating microscopy studies, start-
ing from relative densities of about 55% (compared to the 
density of glass monoliths). Results from heating micros-
copy and DTA summarized in Table 3 directly relate to the 
shrinkage during sintering and show dramatic differences 
between Bioglass 45S5 and the other glasses investigated 
here: While all other glasses reached a relative density of 
≥94% at the end of shrinkage, Bioglass 45S5 reached about 
67% only. This suggests that 45S5 did not sinter to compact 
specimens during the heating process but that a significant 
amount of porosity remained. Indeed, this poor sintering 
ability of 45S5 has been reported previously: Arstila and 
co‐authors21 noted that Bioglass 45S5 devitrified upon heat-
ing without any noticeable sintering before melting, and 
that cube‐shaped monoliths of 45S5 crystallized upon heat 
treatment but retained their shape, in contrast to monoliths 
of other bioactive glass compositions which became more 
rounded.22 This agrees well with results of SEM (Figure 
2) and µCT studies here (Figure 3). Figure 2A shows SEM 
micrographs of powder compacts of 45S5 heated close to 
the end of shrinkage temperature, TSE (Table 3). They show 
the presence of individual, non‐rounded particles, seeming 
to be poorly sintered together. Even at higher temperatures 
(810°C, Figure 2B) the particle shape had not changed 
much. By contrast, individual particles could not be distin-
guished any longer for any of the other glasses heated close 
to the end of shrinkage temperature (Figure 2C‐H), visible 
pores seemed small in number and size and often rounded 
in shape, confirming good sintering by viscous flow. µCT 
scans provided more detailed insight into changes in rela-
tive density and pore volume during sintering. The relative 
density of 45S5 changed from 55.7% (Figure 3A) near the 
onset of shrinkage temperature (580°C) to 65.6% (Figure 
3B) at 710°C, well beyond the end of shrinkage temperature. 
Glass 45S5 13‐93 ICIE16 F0 F1 F3 F8
D10 1.96 1.64 1.82 1.78 1.84 2.00 2.01
D50 11.65 9.08 10.81 10.26 9.95 11.26 11.21
D90 31.48 27.42 28.42 28.99 28.30 29.19 31.22
T A B L E  2  Particle size distribution 
data (in µm) for milled glass powder 
(“<32 µm”)
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3D visualizations illustrate the significant amount of pore 
volume present, corresponding to 44.3% and 34.4%, re-
spectively. For glass F3, the change in relative density was 
much more pronounced, densifying from 68.3% below the 
onset of shrinkage temperature (570°C) to 96.3% at 720°C 
(Figure 3C,D). 3D visualizations also highlighted the corre-
sponding dramatic reduction in pore volume during sinter-
ing of glass F3 from 31.7% to 3.7%.
Comparing the results for the relative density of sintered 
powder compacts from heating microscopy (Figure 1A,B) 
and µCT (Figure 3), it is interesting to note that both meth-
ods give comparable results, although in heating microscopy 
relative densities were obtained from silhouette images rather 
than analyzing the entire three‐dimensional structure as in 
µCT.
Differential thermal analysis curves (Figure 1C; results 
summarized in Table 3) of the glasses, with the exception of 
45S5, showed the presence of marked shoulders above Tg, 
indicating the beginning of sintering. Heating microscopy 
allowed for precise measurement of the onset of shrink-
age (Figure 1A,B; Table 3), which occurred about 30‐50 K 
above Tg. The last column in Table 3 shows the tempera-
ture range between the end of sintering and the onset of 
crystallization, TCO‐TSE, which relates to the sintering abil-
ity. For full densification, positive values are needed, and 
the amount of the positive deviation from zero provides a 
measure for the processing or sintering ability of a glass. 
Of the glasses studied here, only 45S5 showed a negative 
value for TCO‐TSE, as the onset of crystallization actually 
occurred at lower temperature than the end of sintering. 
Figure 1D compares the trends of Tg vs TSO as well as TSE 
vs TCO. Tg and TSO followed the same trend for all glasses 
studied here: similar to the trend for the sintering shoul-
der in DTA curves, TSO also was about 30‐50 K above Tg. 
F I G U R E  1  (A,B) Relative silhouette 
area (sA) vs temperature during heating 
microscopy studies on glass powder 
compacts: (A) well‐known glasses Bioglass 
45S5, 13‐93, ICIE16, and fluoride‐free glass 
F0; (B) glasses F0 to F8. Relative density 
values (ρrel) were calculated according to 
Equation 1. Arrows indicate shrinkage onset 
temperature, TSO (+; dsA/Dt < −0.3%/10 K) 
and shrinkage end temperature, TSE  
( ; dsA/dT < 0.3%/10 K). (C) differential 
thermal analysis curves for glass powders 
<32 µm. Arrows indicate glass transition 
temperatures (Tg, ), onset (TCO, ) and 
end temperature (TCE, ) of the first 
crystallization peak and the first detectable 
liquidus temperature (TL, ). (D) Tg, TSO, 
TSE, and TCO of the glasses. (E) Tg and TCO 
of fluoride‐containing glasses (left axis) and 
the processing window, TCO‐Tg (blue, right 
axis) vs their nominal CaF2 content (lines 
are visual guides only)
T A B L E  3  Characteristic process temperatures for glass powder 
compacts: Tg (  in Figure 1C), TSO (+ in Figure 1A,B), TSE (᠅ in 
Figure 1A,B), TCO (   in Figure 1C) (all in °C) and the temperature 
ranges TSO‐Tg and TCO‐TSE (in K)
Glass Tg TSO TSO‐Tg TSE TCO TCO‐TSE
45S5 526 560 34 623 591 −32
13‐93 586 632 46 738 914 176
ICIE16 610 640 30 741 778 37
F0 598 648 50 750 785 35
F1 587 628 41 740 778 38
F3 540 590 50 680 690 10
F8 534 570 36 670 688 18
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This should not come as a surprise, as for example, IUPAC 
defines Tg by the viscosity of the glass (1013 dPa s). The 
viscosity for the sintering of a porous body lies at approx-
imately 108.8‐108 dPa s, that for the sintering of solid bod-
ies at about 106  dPa  s.23 For most of the glasses studied 
here, TSE and TCO seemed to follow a similar trend, too. 
There are two notable exceptions, however: 45S5, where 
TCO actually occurred at lower temperatures than the end 
of shrinkage, as mentioned above, and 13‐93, where TCO 
appeared at significantly higher temperatures than TSE. The 
reason for comparable temperature ranges between TSE and 
TCO for most of the other glasses may be their similarity 
in structure (NC = 2.1) and composition. 13‐93, however, 
has a much higher network connectivity (Table 1) than the 
other glasses studied here, owing to its larger SiO2/modifier 
oxide ratio. Indeed, it has been noted before that bioactive 
glasses with a higher SiO2 content showed much improved 
processing.24 The large temperature range between TSE and 
TCO for 13‐93 is therefore likely to be caused mainly by its 
higher network connectivity, but other factors may play a 
role as well: MgO incorporation25 and mixed alkali effect26 
both have been shown to widen the temperature range be-
tween Tg and crystallization. 13‐93 has early been identified 
as a bioactive glass of good high temperature processing24 
F I G U R E  2  Fractured cross‐sections 
of powder compacts prepared from milled 
glass powders after heating microscopy 
treatment to the temperature indicated 
followed by quenching in air
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F I G U R E  3  3D X‐ray micro computed tomography images of powder compacts prepared from glass powders <32 µm (A‐D) or particles of 
the fraction 180‐200 µm (E) after heating microscopy treatment to the temperature indicated followed by quenching in air. Images on the left show 
the actual solid glass ("struts"), while the images on the right show the pore volume ("pores")
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and comparably low crystallization tendency.27 It has been 
used successfully for the sintering of porous scaffolds by 
varying methods such as foam replication technique28 or 
unidirectional freezing29 or the preparation of glass fibres 
by drawing from pre‐forms,21 from the melt21 or by melt 
spinning.30 13‐93 also shows bone bonding in vivo.31,32
As Bioglass 45S5 was the first bioactive glass devel-
oped and also has been used clinically with great success, 
several studies have looked into its sintering and crystal-
lization behavior, mostly with regard to the preparation 
of scaffolds. Bretcanu et al33 investigated the sintering 
behavior of fine powder (mean particle size  <  5  µm) of 
F I G U R E  4  Fourier‐transform infrared spectra of the glass powders (A) before heat treatment, (B) of powder compacts treated in the heating 
microscope to TSE, (C) powder compacts of 45S5 or 13‐93 or (D) F3 treated in the heating microscope to various temperatures followed by 
quenching in air. Bands labelled a to d are discussed in the text. X‐ray diffraction patterns of powder compacts treated in the heating microscope 
to (E) TSE or (F) higher temperatures as indicated, followed by quenching in air. Crystal phases are #wollastonite, CaSiO3; *Na2CaSi2O6 (or 
Na2Ca2Si3O9), and $silicorhenanite, Na2Ca4(PO4)2SiO4
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commercial 45S5 samples using heating microscopy and 
found that in addition to a sintering range between 500 and 
600°C (approximately the same temperature range as the 
one investigated in the present study) a second sintering 
range could be detected at higher temperature between 
850 and 1000°C. According to our DTA results presented 
here, this second sintering range is still below the liquidus 
temperature. Based on these results, Bretcanu et al chose 
1050°C as their optimum sintering temperature. The au-
thors identified a sodium calcium silicate, Na2Ca2Si3O9, 
crystal phase, irrespective of the temperature studied. The 
authors also detected silicorhenanite, Na2Ca4(PO4)2SiO4, 
as a minor, secondary phase.33 Further crystallization 
studies on 45S5 indicated a variation in the crystallization 
mechanism with particle size, that is, with coarse or fine 
powder, and the authors suggested that the crystallization 
mechanism might be more complex than a simple nucle-
ation and growth process and possibly involved phase sep-
aration.34 Later studies confirmed that the nature of phase 
separation indeed had an influence on 45S5 crystallization 
and that this effect was much less pronounced for powder 
than for bulk samples.35
Densification of porous glass bodies during heat treat-
ment is driven by the particles' surface energy, and the sur-
face area is minimized through viscous flow.36 However, if 
crystallization occurs at the same time, particularly surface 
crystallization, viscous flow is affected as the crystallized 
surface does not flow and, as a result, the sintering process 
is slowed down or inhibited.36 If crystallization produces a 
residual glassy phase of which the composition (and thus the 
viscosity) differs from that of the original glass, viscous flow 
sintering may be affected even in the absence of crystalline 
surface layers.36 Considering the narrow processing window 
of Bioglass 45S5,37,38 it is likely that surface crystallization is 
the reason for its poor densification during sintering, and, in-
deed, this has been reported earlier.33,39 Uniaxial load applied 
during sintering has been shown to help to achieve full den-
sification for 45S5, and it also helped to reduce the sintering 
temperature from 1050°C to 610°C.40
Crystallization can be followed by structural analyses 
such as vibrational spectroscopy or XRD. FTIR spectra of the 
untreated glasses (Figure 4A) showed the typical shape for 
bioactive glasses, characterized by a bridging oxygen (BO) 
band at about 1000 cm−1 (band a) and two non‐bridging ox-
ygen (NBO) bands at about 900 and 850 cm−1 (b and c). For 
13‐93, the spectrum looked slightly different, as the NBO 
band (c) at 850 cm−1 was absent, owing to the lower modifier 
content and higher network connectivity (Table 1) compared 
to the other glasses studied here. FTIR spectra of powder 
compacts heat‐treated to TSE (Figure 4B) showed changes for 
45S5 only. The shape of bands b and c in the BO and NBO 
region had changed markedly, with features having become a 
lot more distinct, suggesting an increased structural order. An 
additional band (d) had appeared at about 600 cm−1, possibly 
related to phosphate species.41 Interestingly, the correspond-
ing XRD pattern of the same 45S5 sample (Figure 4E) did not 
show any indication for the presence of crystalline phases, 
with only an amorphous halo being visible. A possible ex-
planation for this difference may be that ATR‐FTIR analyses 
are better suited to detect surface features than XRD analyses 
are. Once 45S5 was treated to higher temperatures (810°C, 
Figure 4F), the amorphous halo had disappeared and reflec-
tions indicated the presence of a crystalline phase, which in 
the literature has been identified as either Na2CaSi2O6,38,42 
or as Na2Ca2Si3O9.33,39,43 Both phases show very similar dif-
fraction patterns, are known to form solid‐solutions within 
the series Na6−2xCac+xSi6O18 (0 ≤ x ≤ 1) and are similar to 
the mineral combeite.44,45 While the FTIR spectra of glasses 
F0 and F1 showed no indication of crystallization, two low‐
intensity reflections were present at about 32 and 33°2θ in the 
XRD patterns of these samples treated to TSE (Figure 4E). In 
the patterns of these glasses treated at higher temperatures, 
the same reflections seemed to be present, but had not in-
creased in intensity. Instead, high intensity reflections corre-
sponding to Na2CaSi2O6 (or Na2Ca2Si3O9) were present. The 
fact that the intensity of the reflections at 32 and 33°2θ did 
not change with heat treatment is interesting. As they cor-
respond to the two highest intensity peaks in the diffraction 
pattern of apatite, and as it has been shown that bioactive 
glass powders can form apatite not only when immersed in 
aqueous solution but also by reactions with atmospheric hu-
midity,46 we cannot exclude that the same has happened here.
Particularly interesting is the difference in the sintering be-
havior of glasses 45S5 and F0, which are actually quite similar 
in composition. The two glasses share the same SiO2 and P2O5 
content and the same network connectivity. However, F0 has 
a larger CaO/alkali metal oxide ratio and also contains two 
types of alkali metal cations, thereby making use of the mixed 
alkali effect, which is known to reduce the crystallization ten-
dency.26 Wallace et al have investigated the effect of the Na2O/
CaO ratio on thermal properties including Tg and crystalliza-
tion temperature.47 Although unfortunately their DSC traces 
are not shown and only crystallization peak temperatures 
(rather than crystallization onset) are given, results suggest 
a trend to a smaller processing window, that is, temperature 
range between Tg and crystallization, with a larger Na2O/CaO 
ratio. Other studies confirmed this by showing that bioactive 
glasses with large alkali metal oxide contents not only showed 
low Tg values but also low crystallization temperatures.21,48,49 
More importantly, these studies highlighted that not only crys-
tallization per se, but particularly the type of crystal phases 
being formed played a major role with regard to the process-
ing behavior of bioactive glasses. The glasses in those studies 
could be grouped according to the main crystal phase being 
formed during heat treatment, as they either crystallized to so-
dium calcium silicates (NCS, including Na2Ca2Si3O9) or to 
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calcium silicate (wollastonite, CaSiO3, CS). Glasses crystal-
lizing to NCS (e.g. 45S5) showed poor processing properties 
and crystallized about 100 K above Tg.49 By contrast, glasses 
crystallizing to CS (e.g. 13‐93), showed much improved pro-
cessing, crystallized at significantly higher temperatures and 
were particularly suitable for processes which involved a large 
surface area to volume ratio, such as sintering of powders. The 
crystal phases formed were controlled via the glass composi-
tion, particularly the Na2O/CaO ratio, with a large ratio favor-
ing crystallization of NCS. Studies by Vedel et al49 found a 
correlation also between the crystal phases being formed upon 
heat treatment (NCS vs CS) and their apatite‐forming ability 
in simulated body fluid (SBF). Glasses which crystallized to 
NCS upon heat treatment tended to form apatite faster, result-
ing in thicker layers, while glasses from the CS group tended 
to be slower in forming apatite.
In the present study, however, there seemed to be no cor-
relation between glass processing and crystal phases formed. 
Except for glass 13‐93, all glasses showed NCS as the main 
crystal phase appearing during heat treatment, despite sig-
nificant differences in their sintering. With increasing CaF2 
content, that is, with increasing Ca/Na ratio, wollastonite 
appeared as a second crystalline phase. This, however, did 
not coincide with a larger temperature range between TSE and 
TCO or between Tg and TCO, and thus does not seem to in-
dicate improved processing here. Although glass ICIE16 is 
known to show significantly better processing at higher tem-
peratures50,51 than 45S5 and also has a much higher CaO con-
tent, both seemed to crystallize to the same phase (Figure 4F), 
possibly because of their similarity in network connectivity.52 
The only difference was that the reflections were better re-
solved for glass ICIE16 (as well as for glass F0‐F8), while 
for example the two peaks at 33.5 and 34.5°2θ overlapped for 
45S5. The reason for this lack of resolution may be the higher 
Na2O content of 45S5 together with the fact that in this region 
formation of solid solutions occurs readily.44,45,53 This may 
have caused peak broadening for 45S5, an effect which has 
been observed previously for similar glass compositions.54 
The main difference between glasses ICIE16 and F0 is their 
phosphate content. While an increase in phosphate content 
has been shown to increase the tendency of a bioactive glass 
to crystallize,55 no such effect was observed here, probably 
because the overall P2O5 contents of both glasses are still 
low. This difference in phosphate content of these two glasses 
has, however, been shown to affect the rate at which apatite 
formed during in vitro immersion experiments.14
Fluoride has been shown to affect the thermal properties 
of bioactive glasses,14,37,43,54 and as a result it also affects the 
sintering behavior here: with increasing CaF2 content, the 
onset of shrinkage moved to lower temperatures. However, 
the trend was not linear. Instead, temperature differences 
between the sintering onset temperatures of F0 vs F1 or F3 
vs F8 were very small, while there was a large gap between 
F1 and F3 (Figure 1B). The same trend was obvious for Tg 
(Figure 1E), which is in contrast to earlier studies on the same 
glass compositions (but different batches),14,37 which showed 
Tg to decrease linearly with increasing CaF2 content. This 
difference may possibly be explained by slight variations in 
the actual CaF2 content of the glasses, as fluoride losses are 
well‐known to occur during melting and are difficult to con-
trol.56 The decrease in Tg, and thus in the onset of shrinkage, 
can be explained by the structural role of fluoride in these 
glasses. Fluoride has been shown to complex modifier ions 
such as calcium and sodium,54,57,58 and to form fluoride‐ and 
modifier‐rich regions or clusters.42,59 The fluoride and mod-
ifier ions in these regions can be expected to show a high 
mobility at elevated temperatures, and they thus lower the 
overall Tg, but also crystallize easily. As a result, for glasses 
F I G U R E  5  (A) Heating microscopy and (B) differential thermal analysis (DTA) results for different particle size fractions of glass F3. (A) 
Relative density values (ρrel) were calculated according to Equation 1. Shrinkage end temperature, TSE, is indicated ( ; dsA/dT < 0.3%/10 K). (B) 
Arrows indicate glass transition temperatures (Tg, ), onset (TCO, ) of the first crystallization peak, crystallization peak temperatures ( , )  and 
the first detectable liquidus temperature (TL,  )
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F0‐F8 the temperature range between TSE and TCO becomes 
smaller with increasing CaF2 content (Figure 1d), indicating 
the influence of even small compositional variation on the 
sintering behavior.
As glass F3 nearly fully densified during sintering of glass 
powders (<32 µm), this composition was chosen for further 
analyses. Figure 5A shows the shrinkage for different particle 
size fractions of glass F3 during heating microscopy. Green 
density of all samples was 61 ± 3%. Results illustrate that 
the shrinkage, and thus the densification during sintering, de-
creased with increasing particle size, changing from nearly 
full densification (ρrel ≥ 94%; particle size <32 µm) to a rela-
tive density of 84% (300‐315 µm). This is expected based on 
classical models of sintering kinetics,60 and it has previously 
been observed for bioactive glasses.61 As a result, sintered 
bodies were more porous if they had been prepared from 
larger particles, with heating microscopy giving a porosity of 
about 15% for particles in the 180‐200 µm size range, com-
pared to virtually no porosity for particles sieved to <32 µm 
(Figure 5A). Results from µCT scans differ less, however 
(Figure 3D,E; F3) showing 5.8% porosity for bodies sintered 
from particles in the 180‐200 µm size range and 3.7% poros-
ity for those sintered from particles sieved to <32 µm. The 
corresponding DTA curves (Figure 5B) show that the pro-
nounced sintering shoulder between Tg and crystallization 
disappeared with increasing particle size. It is interesting to 
note that the temperature of maximum densification (TSE in-
dicated in Figure 5A) clearly correlates with the onset of the 
first crystallization peak observed in DTA curves for parti-
cle size fractions <32, 56‐63 and 180‐200 µm. This, again, 
indicates that sintering is strongly affected by beginning 
crystallization. It is known that viscous sintering can be fully 
impeded by the presence of a compact crystal surface layer, 
regardless of its volume fraction.62,63 The trend for onset tem-
perature and peak height observed in Figure 5B suggests that 
crystallization affected sintering of the largest particle size 
fraction (300‐315 µm) as well, even though the first crystalli-
zation peak was much weaker in intensity and a second broad 
crystallization peak appeared at higher temperature.
Figure 6A‐D show SEM micrographs of fractured cross‐
sections of sintered F3 powder compacts (180‐200  µm) 
heated to various temperatures above their shrinkage end 
temperature (690°C). At 721°C (Figure 6A), rounded par-
ticles revealed progressive viscous flow and sintering. The 
presence of porosity, which had been quantified as about 
15% (based on density measurements, Figure 5A) or 5.8% 
F I G U R E  6  (A‐E) Scanning electron 
microscopy micrographs of fractured 
cross sections of powder compacts of 
glass F3 (particle size range 180‐200 µm) 
and (F) results of energy dispersive X‐ray 
measurement on (a) a glass grain and (b) a 
crystallized region as indicated in (E)
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(based on µCT on a separate specimen undergoing an identi-
cal heat treatment; Figure 3E), and the irregular shape of the 
pores, however, clearly indicate that sintering was inhibited 
compared to powder compacts of smaller particles (Figures 
2G and 3D,E), although the micrographs showed no appar-
ent presence of crystal phases. Even a very thin crystalline 
layer could possibly prevent shrinkage, though, and some 
small (micrometre‐size range; Figure 6B) heterogeneities 
were indeed apparent from 750°C. Fully sintered particle 
agglomerates appeared, with former grain boundaries being 
visible as thin crystalline ("surface") layers. When heating 
to temperatures ≥800°C (Figure 6C,D), that is, above the 
second DTA crystallization peak, pronounced surface crys-
tallization and a significant crystalline volume fraction be-
came evident. Figure 6E shows the sample treated to 750°C 
in more detail. The non‐crystalline parts of the particles are 
shown as homogeneous light grey areas (a), while crystal-
line parts can be distinguished by their darker shade (b). 
The inset clearly confirms the presence of a crystalline sur-
face layer, about 5 µm in thickness, on the particles. EDX 
analyses (Figure 6F) in region b show an increased sodium 
content and reduced potassium content compared to the non‐
crystalline parts (a).
X‐ray diffraction patterns (Figure 7A) of F3 glass powder 
compacts (<32 µm) showed a pronounced amorphous halo at 
about 28 to 33°2θ for the non‐heat treated sample. With increas-
ing temperature, this amorphous halo became less pronounced, 
but until 710°C no crystalline reflections were detected. 
Similarly, FTIR spectra (Figure 4D) of heat‐treated F3 did not 
show any changes up to that temperature, despite the crystal-
lization onset temperature for this particle size fraction having 
been found to be 690°C by DTA. This discrepancy in tempera-
ture may originate, however, from two different instruments 
having been used for thermal analysis (DTA) and heat treat-
ment/sintering (heating microscope). At higher temperatures, 
FTIR spectra started showing a sharpening of the NBO silicate 
band (b) at 914 cm−1 and, to some extent, the BO band (a) at 
1020 cm−1 as well as the appearance of a pronounced phos-
phate band (d) at 623 cm−1. From 730°C, high intensity reflec-
tions in XRD patterns indicated the presence of Na2CaSi2O6 
(or Na2Ca2Si3O9) (Figure 7A). The first crystallization peak 
in DTA traces (at 720°C) can therefore be attributed to for-
mation of one of these phases (or possibly a mixture). When 
heating to 950°C, that is, well above the weak DTA shoulder 
at 740°C and the weak DTA peak at 820°C (Figure 5B), addi-
tional reflections appeared. One of them was identified as the 
apatite‐like silicorhenanite, Na2Ca4(PO4)2SiO4, which has pre-
viously been shown to crystallize from bioactive glasses.33,64,65 
The remaining, minor phase (or phases) with main reflections 
appearing in the range of 30 to 32°2θ, could not be identified 
unambiguously, but considering the appearance of a phosphate 
band in FTIR spectra may well relate to an orthophosphate, 
which also has been reported previously.42 The detailed assign-
ment of these secondary crystal phases, which probably had a 
negligible influence only on the sintering in the temperature 
range studied here, will require further analyses and is beyond 
the scope of the present study.
X‐ray diffraction patterns of sintered powder compacts 
obtained from coarse particle size fractions (56‐63, 180‐200, 
or 300‐315  µm) heat‐treated to two different temperatures 
(Figure 7B) also showed Na2CaSi2O6 (or Na2Ca2Si3O9) as 
the main crystal phase. For particle size 300‐315 µm, the re-
flections were rather weak at 750°C, as the first DTA crys-
tallization peak was also weak (Figure 5B), but reflections 
increased in intensity for 850°C, i.e. above the second DTA 
crystallization peak. This finding indicates that the first and 
second DTA peaks did not correspond to different crystal 
phases but could be connected to different modes of overall 
crystallization of Na2CaSi2O6 (or Na2Ca2Si3O9). Such behav-
ior has been observed for strong surface nucleation, where 
a thin, dense crystalline surface layer (as seen in Figure 6) 
F I G U R E  7  X‐ray diffraction patterns of (A) F3 powder 
compacts (<32 µm) treated in the heating microscope to different 
temperatures and of (B) F3 for grain size fractions 56‐63 µm, 
180‐200 µm or 300‐315 µm heated to temperatures of the 1st and 
2nd differential thermal analysis crystallization peak. Crystal 
phases are *Na2CaSi2O6 (or Na2Ca2Si3O9) and $silicorhenanite, 
Na2Ca4(PO4)2SiO4
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was formed at early stages, causing a first DTA peak, while 
its volume fraction was still small for coarse glass particles. 
Once the surface is completely coated by a crystalline layer, 
lateral crystal growth is impeded and crystals grow towards 
the bulk instead (as seen in Figure 6D, 883°C), which some-
times causes a second DTA peak.62,66‒68 The XRD patterns 
in Figure 7B also show the presence of minor phases, for ex-
ample, silicorhenanite, Na2Ca4(PO4)2SiO4, similar to those 
observed above for smaller particle sizes.
Sintering studies here were performed on compact pel-
lets, and further studies are necessary to investigate the 
preparation of highly porous 3D scaffolds. Depending on the 
method chosen for scaffold preparation, for example, foam 
replication technique,28 gel‐cast foaming50 or additive man-
ufacturing,69 too low a viscosity of the glass during sinter-
ing may possibly result in the collapse of the pore structure. 
Here, beginning crystallization might provide a stabilizing 
effect and may thus be advantageous for certain bioactive 
glass compositions.
4 |  CONCLUSIONS
Taken together our results show that while crystallization 
inhibits complete sintering of Bioglass 45S5 at temperatures 
around 600°C, crystallization does not necessarily prevent 
the dense sintering of bioactive glasses, depending on the 
glass composition. Here we demonstrate that using glasses 
with a large alkaline earth to alkali metal oxide ratio, mixed 
alkali compositions as well as a low fluoride content, com-
positions can be obtained which sinter by viscous flow to 
nearly fully densified specimens. This happens even if the 
glass network connectivity remains the same as for Bioglass 
45S5. Only with increasing particle size sintering is increas-
ingly inhibited by surface crystallization of Na2CaSi2O6 
(or Na2Ca2Si3O9), resulting in sintered specimens with in-
creased remaining porosity. Bioactive glass sintering and 
the remaining micro‐porosity can thus be tailored by vari-
ation of modifier type and glass particle size, allowing for 
flexibility in the design and preparation of porous bioactive 
glass scaffolds.
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